Multi-Omics Data Analysis Revolutionizes Heart Drug Discovery

Multi-Omics Data Analysis Revolutionizes Heart Drug Discovery

Multi-omics data analysis is revolutionizing the way we approach heart drug discovery. Cambridge-based CardiaTec recently raised $6.5 million to accelerate drug discovery efforts targeting cardiovascular diseases such as heart attacks and strokes.

With cardiovascular diseases being the leading cause of death worldwide, understanding their biology remains a significant challenge. CardiaTec aims to tackle the gap in knowledge by leveraging an innovative drug discovery platform that uses artificial intelligence to analyze multi-omics data derived from human tissues.

Understanding Multi-Omics and Its Importance

Multi-omics refers to the analysis of various sets of biological molecules within an organism, including the genome, transcriptome, proteome, and epigenome. By employing this analytical approach, CardiaTec can investigate the complex relationships across biological layers to gain insights into how cardiovascular diseases develop.

Uncovering Drug Targets

• Identifying Specific Molecules: The startup focuses on uncovering drug targets—specific molecules involved in disease progression that can be influenced by drug therapy.
• Computational Methods: CardiaTec uses computational techniques to identify and prioritize dysregulated drug targets and associated pathways.
• Innovative Drug Target Discovery: This method increases the likelihood of successful preclinical trials and clinical applications, enhancing therapeutic outcomes.

As part of its mission, CardiaTec is also building the largest human heart tissue multi-omics dataset, collaborating with a network of 65 hospitals across the UK and US.

Following this investment round, the company plans to expand its platform and advance proprietary drug targets towards preclinical stages. Co-founder and CEO Raphael Peralta noted they have already identified their first therapeutic targets.

Founded in 2021, CardiaTec emerged from the Han Lab at the University of Cambridge, with a team dedicated to redefining cardiovascular drug discovery.